PACB Mar 2020 5.000 put

OPR - OPR Delayed Price. Currency in USD
0.5000
0.0000 (0.00%)
At close: 2:20PM EST
Stock chart is not supported by your current browser
Previous Close0.5000
Open0.5000
Bid0.3000
Ask1.0000
Strike5.00
Expire Date2020-03-20
Day's Range0.5000 - 0.5000
Contract RangeN/A
Volume10
Open Interest507
  • Sequencing giant Illumina scraps $1.2 billion PacBio acquisition
    American City Business Journals

    Sequencing giant Illumina scraps $1.2 billion PacBio acquisition

    Genetic sequencing giant Illumina Inc. has nixed its $1.2 billion acquisition attempt of Menlo Park's Pacific Biosciences amid intense regulator scrutiny. San Diego-based Illumina announced the all-cash deal to purchase its smaller competitor in 2018, but it has faced an uphill battle to convince regulators in the U.S. and Europe. In October, antitrust regulators in the UK put out a statement of concern about the proposed merger given Illumina's immense market power in the highly-concentrated DNA sequencing industry.

  • TheStreet.com

    U.S. Kills Iranian General, Oil Prices Surge, FOMC to Release Minutes - 5 Things You Must Know Friday

    U.S. stock futures sink and oil prices surge after a U.S. military strike kills Gen. Qassem Soleimani, a top Iranian general; the U.S. economic calendar includes the ISM Manufacturing Index for December and minutes from the Federal Reserve's Dec. 10-11 meeting; Illumina abandons $1.2 billion acquisition of Pacific Biosciences.

  • Illumina and Pacific Biosciences Call Off $1.2 Billion Deal
    Bloomberg

    Illumina and Pacific Biosciences Call Off $1.2 Billion Deal

    (Bloomberg) -- Illumina Inc. and Pacific Biosciences of California Inc. called off their planned $1.2 billion deal after U.S. antitrust enforcers last month moved to block the merger of the DNA-sequencing companies.The transaction had been on hold for more than a year after being announced in November 2018. But antitrust authorities in the U.S. and the U.K. had pushed back against it, and the U.S. Federal Trade Commission filed a complaint to block it last month.“Considering the lengthy regulatory approval process the transaction has already been subject to and continued uncertainty of the ultimate outcome, the parties decided that terminating the agreement” was the best option, the companies said in a joint statement Thursday.Both companies make DNA sequencing machines, a fast-growing segment of the biotechnology and medical sectors driven by demand from drugmakers, hospitals and research institutions. Illumina will pay Pacific Biosciences a $98 million termination fee.Shares of Menlo Park, California-based Pacific Biosciences gained 3.5% to $5.34 per share in New York trading after the markets closed; the stock had been trading well below the deal’s $8-a-share value. Illumina shares were unchanged.Gail Levine, deputy director of the FTC’s Bureau of Competition, said in a statement Thursday that calling off the deal would preserve a more vibrant market.“This deal threatened to let a monopolist extinguish nascent competition in a growing health care market: next-generation DNA sequencing. Customers across the United States and the world will now continue to benefit from the independent innovative efforts of these companies to develop faster, better, and less expensive next-generation DNA sequencing technologies,” Levine said.Her remarks echoed comments in December when the commission moved to block the transaction. And Illumina said at the time it would keep working to get the deal through while examining its options. “It is not clear that we will be able to secure the required regulatory approvals to allow this transaction to close,” Illumina spokesman Eric Endicott said in an email Thursday. “We believe it is in the best interest of both companies’ shareholders and employees to terminate this agreement now.”One recent analysis by Morningstar Inc. estimated that Illumina controls more that 70% of the market for sequencing the human genome. Its DNA-sequencing machines range from bench-top devices to high-end sequencers that can cost as much as $1 million each, and are used in drug discovery, medicine, biological research and consumer testing.Pacific Biosciences’s machines use a different type of technology, which can decode extensive stretches of DNA with a high degree of accuracy. Unlike the technology Illumina’s machines use, it can read some particularly difficult-to-analyze circumstances. At the time the deal was announced, Illumina said the takeover could help lower the cost of long-read sequencing from $12,000 to $1,000.(Updates Pacific Biosciences shares in the fifth paragraph)\--With assistance from David McLaughlin.To contact the reporter on this story: Kristen V. Brown in San Francisco at kbrown340@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2020 Bloomberg L.P.

  • MarketWatch

    Illumina, Pacific Biosciences drop $1.2 billion merger agreement

    Illumina Inc. and Pacific Biosciences of California Inc. on Thursday said they have agreed to drop plans to merge. Under the merger agreement, announced Nov. 1, Illumina would have paid $1.2 billion in cash for Pacific Biosciences. The news sent Pacific Biosciences shares down 3% in after-hours trading. The lengthy regulatory approval process required for the transaction "has already been subject to and continued uncertainty of the ultimate outcome," the companies said in a joint news release. As part of the merger agreement, Illumina will pay Pacific Biosciences a termination fee of $98 million. The announcement was made after markets closed.

  • Business Wire

    Illumina and Pacific Biosciences Announce Termination of Merger Agreement

    Illumina, Inc. (NASDAQ:ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate their merger agreement, previously announced on November 1, 2018, under which Illumina would acquire Pacific Biosciences at a fully diluted enterprise value of approximately $1.2 billion in an all-cash transaction.

  • Here's Why You Should Retain Pacific Biosciences Stock Now
    Zacks

    Here's Why You Should Retain Pacific Biosciences Stock Now

    Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.

  • MarketWatch

    Pacific Biosciences stock falls on FTC challenge to Illumina deal

    Shares of Pacific Biosciences of California Inc. tumbled 3% in morning trading the day after the Federal Trade Commission announced plans to challenge Illumina Inc.'s plans to buy the genetic sequencing company. The regulator said Dec. 17 that Illumina is trying to "unlawfully maintain its monopoly in the U.S. market for next-generation DNA sequencing" by buying Pacific, a potential competitor. Shares of Illumina, which proposed to buy Pacific Biosciences for $1.2 billion in November 2018, are down 0.3%. "We strongly disagree with the FTC's decision and will continue to work through the regulatory approval process as we consider next steps," an Illumina spokesperson said in an email. Year-to-date, Pacific's stock is down 30%, while shares of Illumina have gained 7%. The Health Care Select Sector SPDR Fund exchange-traded fund has gained 17% year-to-date.

  • Benzinga

    The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 17) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: ...

  • Hedge Funds Have Never Been This Bullish On Pacific Biosciences of California, Inc. (PACB)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Pacific Biosciences of California, Inc. (PACB)

    Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]

  • Pacific Biosciences (PACB) Up 2.7% Since Last Earnings Report: Can It Continue?
    Zacks

    Pacific Biosciences (PACB) Up 2.7% Since Last Earnings Report: Can It Continue?

    Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Here's Why You Should Hold on to Pacific Biosciences Stock
    Zacks

    Here's Why You Should Hold on to Pacific Biosciences Stock

    Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.

  • Options Traders Expect Huge Moves in Pacific Biosciences (PACB) Stock
    Zacks

    Options Traders Expect Huge Moves in Pacific Biosciences (PACB) Stock

    Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately.

  • Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates
    Zacks

    Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates

    Pacific Biosciences (PACB) gains from solid segmental contributions in the third quarter.

  • Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates

    Pacific Biosciences (PACB) delivered earnings and revenue surprises of -26.67% and -21.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Pacific Biosciences of California, Inc. Announces Third Quarter 2019 Financial Results

    MENLO PARK, Calif., Nov. 07, 2019 -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company’) today announced financial results for its third quarter ended.

  • Will Pacific Biosciences of California (PACB) Report Negative Q3 Earnings? What You Should Know
    Zacks

    Will Pacific Biosciences of California (PACB) Report Negative Q3 Earnings? What You Should Know

    Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Hedge Funds Have Never Been More Bullish On Pacific Biosciences of California, Inc. (PACB)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Pacific Biosciences of California, Inc. (PACB)

    Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat the S&P […]

  • GlobeNewswire

    Highly Accurate SMRT Sequencing for Human Genetics to Be Showcased at ASHG 2019 Annual Meeting

    MENLO PARK, Calif., Oct. 10, 2019 -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and.

  • Here's Why You Should Retain Pacific Biosciences For Now
    Zacks

    Here's Why You Should Retain Pacific Biosciences For Now

    Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, contraction in gross margin remains a woe.

  • Why Is Pacific Biosciences (PACB) Up 0.2% Since Last Earnings Report?
    Zacks

    Why Is Pacific Biosciences (PACB) Up 0.2% Since Last Earnings Report?

    Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Merger or Not, Pacific Biosciences Needs to Deliver
    Motley Fool

    Merger or Not, Pacific Biosciences Needs to Deliver

    The DNA sequencing pioneer promised a $1,000 human genome by early 2019. The price isn't so important, but the technology upgrades will prove critical.

  • Pacific Biosciences (PACB) Beats on Q2 Earnings & Revenues
    Zacks

    Pacific Biosciences (PACB) Beats on Q2 Earnings & Revenues

    Pacific Biosciences (PACB) Q2 results gain from higher revenues and strong segmental performance. Contraction in gross margin remains a woe.

  • Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates

    Pacific Biosciences (PACB) delivered earnings and revenue surprises of 11.11% and 10.58%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Analysts Estimate Pacific Biosciences of California (PACB) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Pacific Biosciences of California (PACB) to Report a Decline in Earnings: What to Look Out for

    Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.